Thermo Fisher Scientific Tocilizumab Chimeric Recombinant Rabbit Monoclonal Antibody (rhPM-1 (Tocilizumab))

Applications

Tested Dilution

Publications

Immunocytochemistry (ICC/IF)

10 µg/mL

-

ELISA (ELISA)

Assay-dependent

-

Inhibition Assays (IA)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG, kappa

Expression System

HEK293 cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

rhPM-1 (Tocilizumab)

Immunogen

This antibody was prepared by CDR grafting of mouse PM-1 antibody onto a human framework regions.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Protein A

Storage buffer

PBS

Contains

0.02% ProClin 300

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

RRID

AB_3074505

Product Specific Information

Specificity: Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.

Target Information

Tocilizumab (Actemra) is a humanized monoclonal antibody that is developed by Hoffmann-La Roche and Chugai for the treatment of patients with rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and blocks its interaction with interleukin 6 (IL-6), hindering IL-6 from exerting its pro-inflammatory effects.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.